Santé Ventures related stories
All articles and analysis
Surgical Safety Technologies lands $15m in Series A financingBased in Toronto, Surgical Safety Technologies is a medical technology company that engineered the OR Black Box, a platform for improving patient safety.
Venture capital’s 2023 Rising Stars (1 of 4)Ibrahim AlSuwaidi, Rosalind Bazany, Jean-François Cochy and Kareem Dabbagh are among the 40 Rising Stars under the age of 40 in Venture Capital Journal's fourth consecutive list.
- Santé raises fourth fund
The Austin-based healthcare and life science-focused venture firm raises $260m.
Santé Ventures names senior associateAustin-based Santé Ventures, a healthcare and life sciences investment firm, has appointed Eric Epstein as senior associate. Previously, he worked at McKinsey & Company where he was an engagement manager.
- Santé Ventures taps McWilliams as venture partner
Austin-based Santé Ventures, a healthcare and life sciences investment firm, has appointed Dennis McWilliams as a venture partner. McWilliams is the founder of SparkMed Advisors.
- Endeavour Vision leads $25 mln Series D in EndoStim
Endeavour Vision led a $25 million Series D financing round in EndoStim, Inc., a medical device company with a neurostimulation therapy for acid reflux. The treatment is currently available in Europe, Latin America, and Asia Pacific, but has not been approved for sale in the U.S. The funding will go in part towards clinical trials. New investors Wellington Partners and Gimv also participated in the funding.
- RiverVest, Sante, Third Point Ventures lead funding in Lyric Pharmaceuticals
RiverVest Venture Partners, Sante Ventures and Third Point Ventures have co-led an initial close of a $20.4 million Series A funding round in Lyric Pharmaceuticals Inc, a clinical stage company developing therapeutics for gastrointestinal disease. Lyric closed an $825,000 seed funding round led by RiverVest last year.
- Laguna Pharmaceuticals grabs $30 mln Series B, also appoints CEO
Laguna Pharmaceuticals, formerly known as ChanRx, has closed $30 million in Series B financing. Versant Ventures and Frazier Healthcare led the round with participation from BioMed Ventures and previous backer Sante Ventures. In addition to the financing, Dr. Jerel Davis of Versant Ventures and Dr. Jamie Topper of Frazier Healthcare have been added to Laguna's board of directors. Also, Laguna Pharmaceuticals has hired Bob Baltera as CEO. Previously, Baltera was CEO of Amira Pharmaceuticals. Laguna Pharmaceuticals is a biopharmaceutical company focused on treating atrial fibrillation and atrial flutter.